Thomas A Hope

List of Publications by Year
in descending order

178 papers	9,075 citations	38742 50 h-index	46799 89 g-index
184 all docs	184 docs citations	184 times ranked	8678 citing authors

#	Article	IF	Citations
1	A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Journal of Nuclear Medicine, 2022, 63, 567-572.	5.0	20
2	Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery, 2022, 171, 47-54.	1.9	13
3	A cost-utility analysis of 18F-fluorocholineâ€“positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery, 2022, 171, 55-62.	1.9	8
4	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
5	Attenuation Coefficient Estimation for PET/MRI With Bayesian Deep Learning Pseudo-CT and Maximum-Likelihood Estimation of Activity and Attenuation. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 678-689.	3.7	4
6	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
7	Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology, 2022, 22, 123-129.	1.1	6
8	Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosensors and Bioelectronics, 2022, 199, 113854.	10.1	10
9	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. Journal of Clinical Oncology, 2022, 40, 1500-1505.	1.6	16
10	Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. Lancet Oncology, The, 2022, 23, e75-e87.	10.7	26
11	PSMA PET in Prostate Cancerâ€”A Biomarker or a Surrogate End Point?â€”Reply. JAMA Oncology, 2022, , .	7.1	0
12	Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.. Journal of Clinical Oncology, 2022, 40, 109-109.	1.6	0
13	Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 167-167.	1.6	0
14	The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.. Journal of Nuclear Medicine, 2022, , jnumed.121.263448.	5.0	20
15	Leadership in Patient Advocacy. Journal of Nuclear Medicine, 2022, 63, 497-499.	5.0	0
16	Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 352-359.	3.8	10
17	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 233-242.	1.3	3
18	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clinical Nuclear Medicine, 2022, 47, 503-511.	1.3	2

#	Article	IF	Citations
19	Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?. Journal of Clinical Oncology, 2022, 40, 2818-2829.	1.6	13
20	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	1.6	5
21	Intraarterial Peptide Receptor Radionuclide Therapy Using ⁹⁰Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2021, 62, 221-227.	5.0	9
22	MR-Based Attenuation Correction for Brain PET Using 3-D Cycle-Consistent Adversarial Network. IEEE Transactions on Radiation and Plasma Medical Sciences, 2021, 5, 185-192.	3.7	22
23	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
24	Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center. Journal of Nuclear Medicine, 2021, 62, 695-699.	5.0	21
25	Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Medicine, 2021, 10, 62-69.	2.8	0
26	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508.	6.4	30
27	Assessment and Comparison of ¹⁸F-Fluorocholine PET and ^{99m}Tc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. Journal of Nuclear Medicine, 2021, 62, 1285-1291.	5.0	21
28	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. Journal of Nuclear Medicine, 2021, 62, 146-148.	5.0	15
29	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
30	PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet, The, 2021, 397, 768-769.	13.7	5
31	Accuracy of ¹⁸F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 1511-1516.	5.0	15
32	The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. European Urology Focus, 2021, 7, 258-266.	3.1	19
33	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	7.0	42
34	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. European Urology Focus, 2021, 7, 238-240.	3.1	31
35	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	1.1	55
36	More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 563.	7.1	1

#	Article	IF	Citations
37	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	7.3	38
38	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.	1.9	13
39	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4463-4471.	6.4	9
40	Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. Journal of Nuclear Medicine, 2021, 62, 1323-1329.	5.0	31
41	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. Translational Andrology and Urology, 2021, 10, 3130-3143.	1.4	9
42	Perspectives on Radiopharmaceutical Agents from the FDA. Journal of Nuclear Medicine, 2021, 62, 881-883.	5.0	1
43	RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials. Journal of Nuclear Medicine, 2021, 62, 1438-1439.	5.0	0
44	Evaluation of attenuation correction in PET/MRI with synthetic lesion insertion. Journal of Medical Imaging, 2021, 8, 056001.	1.5	3
45	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
46	Pitfalls on PET/MRI. Seminars in Nuclear Medicine, 2021, 51, 529-539.	4.6	11
47	Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Physics in Medicine and Biology, 2021, 66, 035016.	3.0	17
48	Harmonization of PET image reconstruction parameters in simultaneous PET/MRI. EJNMMI Physics, 2021, 8, 75.	2.7	2
49	Response to â€œPreoperative localization in primary hyperparathyroidism: Views from the developing worldâ€. Surgery, 2021, , .	1.9	0
50	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S.	5.0	14
51	Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of Nuclear Medicine, 2020, 61, 189-193.	5.0	19
52	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 1-33.	1.1	226
53	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 863-881.	1.1	88
54	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Journal of Thoracic Oncology, 2020, 15, 1577-1598.	1.1	58

#	Article	IF	Citations
55	PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 369-380.	1.1	9
56	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74
57	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095.	5.0	6
58	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 2020, 49, 723-728.	1.1	6
59	A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope. Journal of Nuclear Medicine, 2020, 61, 477-479.	5.0	1
60	Bone material analogues for PET/MRI phantoms. Medical Physics, 2020, 47, 2161-2170.	3.0	8
61	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	1.6	107
62	NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2020, 61, 222-227.	5.0	77
63	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	5.0	10
64	Factors Predicting Metastatic Disease in ⁶⁸Ga-PSMA-11 PETâ€“Positive Osseous Lesions in Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1779-1785.	5.0	15
65	Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study. EJNMMI Research, 2020, 10, 128.	2.5	22
66	68Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality. EJNMMI Physics, 2020, 7, 54.	2.7	3
67	Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.. Journal of Clinical Oncology, 2020, 38, 5502-5502.	1.6	18
68	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2020, 38, 24-24.	1.6	5
69	From Compassionate Use to Phase 3 Trial: The Impact of Germanyâ€™s PSMA-617 Literature (perspective on) Tj ETQq1 1 0.784314 r 255S-262S.	5.0	8
70	Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET. Journal of Nuclear Medicine, 2020, 61, 1764-1764.	5.0	10
71	Introduction to the D-SPECT for Technologists: Workflow Using a Dedicated Digital Cardiac Camera. Journal of Nuclear Medicine Technology, 2020, 48, 297-303.	0.8	9
72	Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. Abdominal Radiology, 2019, 44, 3508-3517.	2.1	22

#	Article	IF	Citations
73	Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Molecular Pharmaceutics, 2019, 16, 3831-3841.	4.6	36
74	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
75	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
76	NANETS/SNMMI Procedure Standard for Somatostatin Receptorâ€"Based Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine, 2019, 60, 937-943.	5.0	95
77	Author Reply. Urology, 2019, 129, 163-164.	1.0	1
78	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology, 2019, 2, 685-690.	5.4	21
79	What is the best PET target for early biochemical recurrence of prostate cancer?â€"Authorsâ€™ reply. Lancet Oncology, The, 2019, 20, e609-e610.	10.7	4
80	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 7448-7454.	7.0	190
81	The use of PET/MRI for imaging rectal cancer. Abdominal Radiology, 2019, 44, 3559-3568.	2.1	19
82	Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. American Journal of Roentgenology, 2019, 213, 266-274.	2.2	18
83	Mucinous rectal cancer: concepts and imaging challenges. Abdominal Radiology, 2019, 44, 3569-3580.	2.1	35
84	¹¹¹In-Pentetreotide Scintigraphy Versus ⁶⁸Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. Journal of Nuclear Medicine, 2019, 60, 1266-1269.	5.0	66
85	Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. Urology, 2019, 129, 165-171.	1.0	41
86	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
87	AUTHOR REPLY. Urology, 2019, 125, 161-162.	1.0	0
88	Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clinical Nuclear Medicine, 2019, 44, e28-e32.	1.3	19
89	Ectopic Thyroid-Stimulating Hormoneâ€"Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by Gallium 68 DOTATATE Positron Emission Tomography/Computed Tomography. World Neurosurgery, 2019, 125, 400-404.	1.3	17
90	Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. Pancreas, 2019, 48, 948-952.	1.1	14

#	Article	IF	Citations
91	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology, 2019, 125, 154-162.	1.0	20
92	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	5.0	35
93	Tumor cell heterogeneity and resistance; report from the 2018 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	2.3	13
94	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clinical Genitourinary Cancer, 2019, 17, e53-e55.	1.9	8
95	Metaanalysis of ⁶⁸Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. Journal of Nuclear Medicine, 2019, 60, 786-793.	5.0	169
96	Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).. Journal of Clinical Oncology, 2019, 37, 363-363.	1.6	22
97	Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. Endocrine Connections, 2019, 8, 1149-1158.	1.9	5
98	Zero TEâ€based pseudoâ€CT image conversion in the head and its application in PET/MR attenuation correction and MRâ€guided radiation therapy planning. Magnetic Resonance in Medicine, 2018, 80, 1440-1451.	3.0	80
99	MRI Contrast Agents. , 2018, , 41-51.		0
100	Hepatobiliary and Pancreatic Cancer PET/MRI. , 2018, , 281-290.		0
101	Letter to the editor response. Abdominal Radiology, 2018, 43, 239-239.	2.1	0
102	LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 149-157.	2.1	82
103	Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI. Journal of Nuclear Medicine, 2018, 59, 852-858.	5.0	206
104	Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 66-74.	5.0	228
105	Motion robust high resolution 3D freeâ€breathing pulmonary MRI using dynamic 3D image selfâ€navigator. Magnetic Resonance in Medicine, 2018, 79, 2954-2967.	3.0	53
106	Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 1627-1633.	2.1	57
107	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdominal Radiology, 2018, 43, 56-74.	2.1	58
108	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	5.0	372

#	Article	IF	Citations
109	Variable refocusing flip angle single-shot fast spin echo imaging of liver lesions: increased speed and lesion contrast. Abdominal Radiology, 2018, 43, 593-599.	2.1	2
110	Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. Molecular Imaging, 2018, 17, 153601211881174.	1.4	6
111	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology, 2018, 289, 730-737.	7.3	114
112	Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results?. American Journal of Roentgenology, 2018, 211, 896-900.	2.2	23
113	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	2.2	25
114	PET/MRI for Gastrointestinal Imaging. Gastroenterology Clinics of North America, 2018, 47, 691-714.	2.2	5
115	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	6.4	116
116	PET/MR Imaging of the Pancreas. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 345-362.	1.1	6
117	Clinical Evaluation of ⁶⁸Ga-PSMA-II and ⁶⁸Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm. American Journal of Roentgenology, 2018, 211, 655-660.	2.2	22
118	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology, 2018, 1, 78-82.	5.4	74
119	Prostate cancer PET tracers: essentials for the urologist. Canadian Journal of Urology, 2018, 25, 9371-9383.	0.0	22
120	Technical Note: Fast respiratory motion estimation using sorted singles without unlist processing: A feasibility study. Medical Physics, 2017, 44, 1632-1637.	3.0	6
121	Hybrid <scp>ZTE</scp>/Dixon <scp>MR</scp>â€based attenuation correction for quantitative uptake estimation of pelvic lesions in <scp>PET</scp>/<scp>MRI</scp>. Medical Physics, 2017, 44, 902-913.	3.0	73
122	Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. Abdominal Radiology, 2017, 42, 870-876.	2.1	24
123	¹⁸F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology, 2017, 284, 460-467.	7.3	73
124	Quantitative Evaluation of Atlas-based Attenuation Correction for Brain PET in an Integrated Time-of-Flight PET/MR Imaging System. Radiology, 2017, 284, 169-179.	7.3	19
125	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589
126	Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. European Journal of Radiology, 2017, 88, 117-128.	2.6	56

#	Article	IF	Citations
127	Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. Clinical Nuclear Medicine, 2017, 42, e218-e220.	1.3	24
128	Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography. Journal of Computer Assisted Tomography, 2017, 41, 376-381.	0.9	9
129	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
130	Evaluation of Sinus/Edge-Corrected Zero-Echo-Timeâ€“Based Attenuation Correction in Brain PET/MRI. Journal of Nuclear Medicine, 2017, 58, 1873-1879.	5.0	40
131	SNMMI Comment on the 2016 Society of Surgical Oncology â€œChoosing Wiselyâ€•Recommendation on the Use of PET/CT in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 11-12.	5.0	3
132	Impact of ⁶⁸Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1956-1961.	5.0	111
133	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, 1247-1262.	3.4	175
134	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, spcone.	3.4	2
135	The Role of PET/MR Imaging in Precision Medicine. PET Clinics, 2017, 12, 489-501.	3.0	7
136	PET/MR Imaging in Gynecologic Oncology. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 667-684.	1.1	21
137	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	5.0	166
138	Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. Clinical and Translational Imaging, 2017, 5, 63-69.	2.1	10
139	Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Research, 2017, 7, 77.	2.5	33
140	Combined parenchymal and vascular imaging: High spatiotemporal resolution arterial evaluation of hepatocellular carcinoma. Journal of Magnetic Resonance Imaging, 2016, 43, 859-865.	3.4	12
141	Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdominal Radiology, 2016, 41, 963-969.	2.1	73
142	Comparison of diffusion-weighted imaging and T2-weighted single shot fast spin-echo: Implications for LI-RADS characterization of hepatocellular carcinoma. Magnetic Resonance Imaging, 2016, 34, 915-921.	1.8	11
143	Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. Abdominal Radiology, 2016, 41, 2161-2168.	2.1	12
144	Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncology, 2016, 12, 2393-2396.	2.4	3

#	Article	IF	Citations
145	Safety and technique of ferumoxytol administration for MRI. Magnetic Resonance in Medicine, 2016, 75, 2107-2111.	3.0	171
146	Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. Surgery, 2016, 160, 747-754.	1.9	27
147	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1611-1620.	6.4	143
148	Transient washout of hepatic hemangiomas: Potential pitfall mimicking malignancy. Radiology Case Reports, 2016, 11, 62-66.	0.6	4
149	Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. Abdominal Radiology, 2016, 41, 1522-1531.	2.1	9
150	Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System. Radiology, 2016, 278, 239-246.	7.3	124
151	Somatostatin Imaging of Neuroendocrine-Differentiated Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, 540-541.	1.3	13
152	Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Physics, 2015, 2, 21.	2.7	27
153	Greater asymmetric wall shear stress in Sievers' type 1/LR comparedÂwith 0/LAT bicuspid aortic valves after valve-sparing aortic root replacement. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 59-68.	0.8	36
154	Transient Respiratory Motion Artifact During Arterial Phase MRI With Gadoxetate Disodium: Risk Factor Analyses. American Journal of Roentgenology, 2015, 204, 1220-1227.	2.2	55
155	Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal Imaging, 2015, 40, 1432-1440.	2.0	91
156	Vascular Imaging With Ferumoxytol as a Contrast Agent. American Journal of Roentgenology, 2015, 205, W366-W373.	2.2	104
157	Hepatobiliary agents and their role in LI-RADS. Abdominal Imaging, 2015, 40, 613-625.	2.0	105
158	MR Imaging of Diffuse Liver Disease. Radiologic Clinics of North America, 2014, 52, 709-724.	1.8	23
159	Neuroendocrine Tumors. Journal of Computer Assisted Tomography, 2014, 38, 898-914.	0.9	6
160	Evaluation of Marfan patients status post valve-sparing aortic root replacement with 4D flow. Magnetic Resonance Imaging, 2013, 31, 1479-1484.	1.8	27
161	Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magnetic Resonance Imaging, 2013, 31, 139-144.	1.8	8
162	Functional and molecular imaging techniques in aortic aneurysm disease. Current Opinion in Cardiology, 2013, 28, 609-618.	1.8	11

#	Article	IF	Citations
163	Improvement of gadoxetate arterial phase capture with a high spatioâ€temporal resolution multiphase threeâ€dimensional SPGRâ€dixon sequence. Journal of Magnetic Resonance Imaging, 2013, 38, 938-945.	3.4	27
164	Gadolinium Accumulation and Fibrosis in the Liver after Administration of Gadoxetate Disodium in a Rat Model of Active Hepatic Fibrosis. Radiology, 2012, 264, 423-427.	7.3	11
165	Intravenous Vasopressin for the Prevention of Nontarget Gastrointestinal Embolization during Liver-directed Cancer Treatment: Experimental Study in a Porcine Model. Journal of Vascular and Interventional Radiology, 2012, 23, 1505-1512.	0.5	4
166	Improved Risk Assessment for Abdominal Aortic Aneurysm Rupture. Journal of the American College of Cardiology, 2011, 58, 2531-2532.	2.8	5
167	4D Flow CMR in Assessment of Valve-Related Ascending Aortic Disease. JACC: Cardiovascular Imaging, 2011, 4, 781-787.	5.3	231
168	Impaired social recognition memory in recombination activating gene 1-deficient mice. Brain Research, 2011, 1383, 187-195.	2.2	37
169	Evaluation of intracranial stenoses and aneurysms with accelerated 4D flow. Magnetic Resonance Imaging, 2010, 28, 41-46.	1.8	79
170	Through Neural Stimulation to Behavior Manipulation: A Novel Method for Analyzing Dynamical Cognitive Models. Cognitive Science, 2010, 34, 406-433.	1.7	13
171	Four-Dimensional Flow Magnetic Resonance Imaging With Wall Shear Stress Analysis Before and After Repair of Aortopulmonary Fistula. Circulation: Cardiovascular Imaging, 2010, 3, 766-768.	2.6	10
172	Bicuspid Aortic Valve: Four-dimensional MR Evaluation of Ascending Aortic Systolic Flow Patterns. Radiology, 2010, 255, 53-61.	7.3	364
173	Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology, 2009, 253, 390-398.	7.3	22
174	Hemodynamics in normal cerebral arteries: qualitative comparison of 4D phase-contrast magnetic resonance and image-based computational fluid dynamics. Journal of Engineering Mathematics, 2009, 64, 367-378.	1.2	63
175	Initial experience characterizing a type I endoleak from velocity profiles using time-resolved three-dimensional phase-contrast MRI. Journal of Vascular Surgery, 2009, 49, 1580-1584.	1.1	13
176	Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine. Investigative Radiology, 2009, 44, 135-139.	6.2	52
177	Imaging of the Thoracic Aorta with Time-Resolved Three-Dimensional Phase-Contrast MRI: A Review. Seminars in Thoracic and Cardiovascular Surgery, 2008, 20, 358-364.	0.6	24
178	Evaluation of Bicuspid Aortic Valve and Aortic Coarctation With 4D Flow Magnetic Resonance Imaging. Circulation, 2008, 117, 2818-2819.	1.6	64